摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,6二硫代双嘌呤 | 49808-20-0

中文名称
6,6二硫代双嘌呤
中文别名
——
英文名称
bis(6-purinyl) disulfide
英文别名
7(9)H,7'(9')H-6,6'-disulfanediyl-bis-purine;Mercaptopurin-disulfid;6,6-Dipurinylsulfid;Mercaptopurine disulfide;6-(7H-purin-6-yldisulfanyl)-7H-purine
6,6二硫代双嘌呤化学式
CAS
49808-20-0
化学式
C10H6N8S2
mdl
——
分子量
302.343
InChiKey
ULNKLXSTZWVSJH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    >219°C (dec.)
  • 沸点:
    447.2±55.0 °C(Predicted)
  • 密度:
    2.06±0.1 g/cm3(Predicted)
  • 溶解度:
    碱性溶液(微溶、加热)、DMSO(微溶)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    160
  • 氢给体数:
    2
  • 氢受体数:
    8

安全信息

  • WGK Germany:
    3

SDS

SDS:0fd8684d012790c30400a9024e6a093f
查看

反应信息

  • 作为反应物:
    参考文献:
    名称:
    PAWELCZYK, EWARYST;ZAJC, MARIA;MAJEWSKI, WIKTOR;MAJEWSKA, BEATA, ACTA POL. PHARM., 45,(1988) N, C. 259-265
    摘要:
    DOI:
  • 作为产物:
    描述:
    6-mercaptopurine 、 potassium iodide 作用下, 以 phosphate buffer 为溶剂, 以41%的产率得到6,6二硫代双嘌呤
    参考文献:
    名称:
    Pazderski; Tousek; Sitkowski, Polish Journal of Chemistry, 2007, vol. 81, # 2, p. 193 - 210
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Synthesis of Bis(7-Methyl-2- or 6-Purinyl) Disulfides
    作者:Alicja Kowalska
    DOI:10.1080/10426500701542734
    日期:2007.10.18
    Substituted 7-methyl-2- or 6-purinethiones were obtained in series of reactions by nucleophilic substitution with oxygen, chloro, and sulfur nucleophiles. Oxidation of the sulfur atom at position 6 or 2 in purinethiones to corresponding disulfides depended on the conditions of the reaction and oxidizing agent.
  • Czauderna, Marian; Samochocka, Krystyna, Journal of the Chemical Society. Perkin transactions II, 1983, p. 765 - 768
    作者:Czauderna, Marian、Samochocka, Krystyna
    DOI:——
    日期:——
  • PEGylated mesoporous silica as a redox-responsive drug delivery system for loading thiol-containing drugs
    作者:Qinfu Zhao、Chen Wang、Ying Liu、Jiahong Wang、Yikun Gao、Xiaojing Zhang、Tongying Jiang、Siling Wang
    DOI:10.1016/j.ijpharm.2014.10.056
    日期:2014.12
    In this paper, we describe the development of a redox-responsive delivery system based on 6-mercaptopurine (6-MP)-conjugated colloidal mesoporous silica (CMS) via disulfide bonds. mPEG was modified on the surface of silica to improve the dispersibility and biocompatiblity of CMS by reducing hemolysis and protein adsorption. The CMS carriers with different amounts of thiol groups were prepared to evaluate the impact of modified thiol on the drug loading efficiency. In vitro release studies demonstrated that the CMS nanoparticles exhibited highly redox-responsive drug release. The cumulative release of 6-MP was less than 3% in absence of GSH, and reached more than 70% within 2 h in the presence of 3 mM GSH. In addition, by comparing the cumulative release profiles of CMS-SS-MP@mPEG with their counterparts without the grafting of hydrophilic PEG, it was found that mPEG chains did not hinder the drug release due to the cleavable disulfide bonds and the improved dispersibility. Overall, this work provides a new strategy to connect thiol-containing/thiolated drugs and hydrophilic polymers to the interior and exterior of silica via disulfide bonds to obtain redox-responsive release and improve the dispersibility and biocompatibility of silica. (C) 2014 Elsevier B.V. All rights reserved.
  • Oligomer-Nucleoside Phosphate Conjugates
    申请人:Ren Zhongxu
    公开号:US20100286084A1
    公开(公告)日:2010-11-11
    The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
  • OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES
    申请人:NEKTAR THERAPEUTICS
    公开号:US20140371168A1
    公开(公告)日:2014-12-18
    The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number administration routes, exhibits advantages over previously administered compounds.
查看更多